Evolving Downstream: JNC’s MLP Technology Addresses the ‘Big Molecule’ Bottleneck in Bioprocessing
As the biopharmaceutical landscape shifts from traditional monoclonal antibodies toward complex viral vectors, mRNA vaccines, and sophisticated cell-based therapies, the...
